2758-98-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Piperazinecarboxylic acid methyl ester is used as a precursor in the synthesis of pharmaceuticals for its ability to contribute to the development of various drug classes, including antihistamines and antipsychotic drugs. Its chemical properties make it a valuable component in the formulation of medications that address a range of health conditions.
Used in Drug Development:
In the realm of drug development, 2-Piperazinecarboxylic acid methyl ester is utilized as a key intermediate in the creation of new drug candidates. Its structural features allow for the exploration of novel therapeutic agents that could potentially offer improved efficacy and safety profiles compared to existing treatments.

InChI:InChI=1/C6H12N2O2/c1-10-6(9)5-4-7-2-3-8-5/h5,7-8H,2-4H2,1H3

Upstream product

• 186581-53-3 diazomethane 
• 2762-32-5 piperazine-2-carboxylic acid 
• 67-56-1 methanol 
• 129799-15-1 piperazine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 107-15-3 ethylenediamine 
• 292638-85-8 acrylic acid methyl ester 
• 171504-98-6 O₁,O₄-di-tert-butyl O₂-methyl piperazine-1,2,4-tricarboxylate 
• 98-97-5 2-pyrazylcarboxylic acid 

Downstream Products

• 129799-08-2 tert-butyl methyl piperazine-1,3-dicarboxylate 
• 129799-11-7 1-benzyl 3-methyl piperazine-1,3-dicarboxylate 
• 1445976-19-1 methyl 1-tert-butoxycarbonyl-4-(N-tert-butoxycarbonylglycyl)piperazine-2-carboxylate 
• 1449505-54-7 C₁₄H₁₆N₂O₄ 
• 1449504-85-1 4-(3-formylbenzoyl)piperazine-2-carboxylic acid 

Relevant academic research and scientific papers

KRAS G12C INHIBITORS

The present invention relates to compounds that, inhibit KRas G12C, In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

Synthesis and catalytic activity of porous polymer containing ionic liquid structures

A novel porous polymer containing ionic liquid (IL) structures was synthesized via quternization and condensation of 4-vinylpyridine and p-xylylene dichloride. The ionic liquid structures were incorporated in the polymeric framework and for this reason bulky IL molecules can hardly block pores and neutralize active sites. The polymer shows a high BET surface area and easily accessible active sites. Catalytically the polymer is very active in Michael additions with averaged yields over 96.0% achieved after short reaction times. The high BET surface, remarkable activity, operational simplicity, wide applicability and improved stability are the key properties of the polymer.

IMIDAZO [4, 5 - B] PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.

Synthesis and biological evaluation of substituted 4-(OBz)phenylalanine derivatives as novel N-type calcium channel blockers

Selective N-type Voltage Activated Calcium Channel (VACC) blockers have shown utility in several models of stroke and pain. In the process of searching for small molecules as N-type calcium channel blockers, we have identified a series of N,N-dialkylpeptidylamines (e.g., PD 175069) with potent functional activity at N-type VACC. Further modification of the leucine moiety of PD 175069 with a cyclized ring structure provides a series of novel molecules. Syntheses and pharmacological evaluation of the series are presented.